TY - JOUR
T1 - Recommendations for liver transplantation for hepatocellular carcinoma
T2 - An international consensus conference report
AU - Clavien, Pierre Alain
AU - Lesurtel, Mickael
AU - Bossuyt, Patrick M.M.
AU - Gores, Gregory J.
AU - Langer, Bernard
AU - Perrier, Arnaud
N1 - Funding Information:
This consensus conference was endorsed and sponsored by the American Association for the Study of Liver Disease (AASLD), American Society of Transplant Surgeons (ASTS), European Association for the Study of the Liver (EASL), European-African Hepato-Pancreato-Biliary Association (E-AHPBA), European Liver and Intestine Transplant Association (ELITA), International Hepato-Pancreato-Biliary Association (IHPBA), International Liver Cancer Association (ILCA), International Liver Transplantation Society (ILTS), and The Transplantation Society (TTS). We acknowledge the generous financial support from the industry including Bayer HealthCare, Novartis, Astellas, Johnson & Johnson, Roche, MSD, AstraZeneca, Nycomed, B Braun, Baxter, MeVis, CAScination, and Microsulis Medical. These companies were neither involved in the selection of topics, nor in the choice of experts or members of the jury. The conference was also supported by a grant from the University of Zurich and the Liver and Gastro-Intestinal Foundation. Finally, we thank Carol De Simio and Stefan Schwyter (University Hospital Zurich) for their help in preparing the figure.
PY - 2012/1
Y1 - 2012/1
N2 - Although liver transplantation is a widely accepted treatment for hepatocellular carcinoma (HCC), much controversy remains and there is no generally accepted set of guidelines. An international consensus conference was held on Dec 2-4, 2010, in Zurich, Switzerland, with the aim of reviewing current practice regarding liver transplantation in patients with HCC and to develop internationally accepted statements and guidelines. The format of the conference was based on the Danish model. 19 working groups of experts prepared evidence-based reviews according to the Oxford classification, and drafted recommendations answering 19 specific questions. An independent jury of nine members was appointed to review these submissions and make final recommendations, after debates with the experts and audience at the conference. This report presents the final 37 statements and recommendations, covering assessment of candidates for liver transplantation, criteria for listing in cirrhotic and non-cirrhotic patients, role of tumour downstaging, management of patients on the waiting list, role of living donation, and post-transplant management.
AB - Although liver transplantation is a widely accepted treatment for hepatocellular carcinoma (HCC), much controversy remains and there is no generally accepted set of guidelines. An international consensus conference was held on Dec 2-4, 2010, in Zurich, Switzerland, with the aim of reviewing current practice regarding liver transplantation in patients with HCC and to develop internationally accepted statements and guidelines. The format of the conference was based on the Danish model. 19 working groups of experts prepared evidence-based reviews according to the Oxford classification, and drafted recommendations answering 19 specific questions. An independent jury of nine members was appointed to review these submissions and make final recommendations, after debates with the experts and audience at the conference. This report presents the final 37 statements and recommendations, covering assessment of candidates for liver transplantation, criteria for listing in cirrhotic and non-cirrhotic patients, role of tumour downstaging, management of patients on the waiting list, role of living donation, and post-transplant management.
UR - http://www.scopus.com/inward/record.url?scp=84855314307&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84855314307&partnerID=8YFLogxK
U2 - 10.1016/S1470-2045(11)70175-9
DO - 10.1016/S1470-2045(11)70175-9
M3 - Review article
C2 - 22047762
AN - SCOPUS:84855314307
SN - 1470-2045
VL - 13
SP - e11-e22
JO - The Lancet Oncology
JF - The Lancet Oncology
IS - 1
ER -